100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

OBJECTIVE: To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. BACKGROUND: Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) and has demonstrated efficacy in reducing migraine h...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Noah, Pearlman, Eric, Ruff, Dustin, Day, Kathleen, Jim Nagy, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221112/
https://www.ncbi.nlm.nih.gov/pubmed/30341990
http://dx.doi.org/10.1111/head.13427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221112/
https://www.ncbi.nlm.nih.gov/pubmed/30341990
http://dx.doi.org/10.1111/head.13427

Ejemplares similares